MUMBAI, India, September 5, 2025 — Glenmark Pharmaceuticals has announced the initiation of a multi-country Phase 3 clinical trial for Envafolimab, a novel subcutaneous PD-L1 inhibitor, aimed at improving outcomes for patients with resectable Stage III non-small cell lung cancer (NSCLC). The trial has received approval from the Drugs Controller General of India (DCGI), enabling patient enrollment and treatment within the country, with further sites being prepared in Russia, Brazil, and Mexico.
Science Significance
Envafolimab is a first-in-class, subcutaneously administered anti-PD-L1 antibody, designed to enhance the immune response against tumors. It consists of a recombinant single-domain anti-PD-L1 molecule fused with the Fc portion of human IgG1, allowing for efficient delivery and targeted action at the tumor site. The trial will assess the efficacy, safety, pharmacokinetics, and immunogenicity of Envafolimab in patients with Stage IIIA and IIIB NSCLC, who are eligible for surgery. Unlike intravenous immunotherapies, Envafolimab offers the convenience of a quick subcutaneous injection, potentially improving treatment adherence and accessibility, especially in regions with limited healthcare infrastructure. Given that NSCLC accounts for 80–85% of lung cancer cases, and 20–30% are diagnosed at Stage III, the development of this therapy addresses a significant unmet medical need in oncology.
Regulatory Significance
The trial’s approval by the DCGI marks a critical regulatory milestone for advancing immunotherapy options in India. The study is aligned with stringent safety and efficacy protocols, ensuring that Envafolimab’s therapeutic profile meets global standards. Parallel trials in China, where Envafolimab is already approved for metastatic cancers, and ongoing efforts to expand into other regions, reflect a broader regulatory push to bring advanced cancer treatments to underserved populations.The trial’s design will allow the collection of robust data that supports future regulatory filings, ensuring that patients can benefit from cutting-edge therapies sooner.
Business Significance
Advertisement
With this trial, Glenmark Pharmaceuticals reinforces its leadership in oncology research, expanding its global footprint through strategic collaborations and licensing agreements. The use of subcutaneous administration technology differentiates Envafolimab in a competitive landscape, offering opportunities for accelerated market penetration and patient-centered delivery.The trial also enhances Glenmark’s presence in emerging markets, where access to innovative therapies is often limited by infrastructure and cost barriers, positioning the company as a pioneer in bringing transformative treatments to global healthcare systems.
Patients Significance
For patients diagnosed with Stage III NSCLC, treatment options remain limited, and long-term survival rates are poor. The introduction of Envafolimab’s subcutaneous immunotherapy offers a more patient-friendly alternative to traditional intravenous treatments, potentially reducing hospital visits and enhancing treatment adherence. By facilitating neoadjuvant and adjuvant therapies, Envafolimab aims to improve the success of surgery while minimizing relapse, ultimately enhancing quality of life and providing hope to individuals facing aggressive cancer forms.
Policy Significance
The trial exemplifies how public health policies and global collaborations can drive innovation in oncology. By supporting expedited clinical research, regulatory agencies are paving the way for therapies that are both effective and accessible. Envafolimab’s approval process and multi-country trial reflect a growing trend of aligning policy frameworks with patient-centric outcomes, emphasizing faster access to treatments that address life-threatening diseases in a cost-effective and scalable manner.
About Glenmark:
Glenmark Pharmaceuticals Ltd. is a research-driven global pharmaceutical company operating in over 80 countries with 11 world-class manufacturing facilities across four continents. With a strong focus on respiratory, dermatology, and oncology treatments, Glenmark ranks among the top global generics and biosimilars companies. The company’s sustainability goals have been validated by the Science Based Target initiative (SBTi), and through multiple CSR programs, Glenmark has positively impacted over 3 million lives in the last decade.
Source: Glenmark Pharmaceuticals Ltd. Press Release
